NeuroScientific Biopharmaceuticals (ASX:NSB) has reached a significant milestone in its clinical development program, announcing TGA approval for the first three patients to receive its proprietary stem cell therapy, StemSmart, under Australia’s Special Access Program for the treatment of fistulising Crohn’s disease. …
NeuroScientific gains TGA approval for first patients in Crohn’s disease program
October 7, 2025 Australian Biotech
Latest Video
New Stories
-
Australians want better access to medical technology, and a clearer pathway to get there
October 28, 2025 - -
Pharmacy Guild backs expanded prescribing rights for optometrists
October 28, 2025 - - Latest News -
PYC reports strong clinical momentum and cash position ahead of key readouts
October 27, 2025 - - Australian Biotech -
Government backs new national push to close bone health testing gap for women
October 27, 2025 - - Latest News -
Leadership change at PolyNovo as long-time Chair steps down
October 27, 2025 - - Australian Biotech -
Cann Group announces major debt restructure and capital raise to strengthen balance sheet
October 27, 2025 - - Australian Biotech -
FDA awards the first-ever national priority vouchers to nine sponsors
October 27, 2025 - - Latest News